Cero Therapeutics Soars 22.55% on Bullish Analyst Upgrade

On June 24, 2025, CERo Therapeutics surged 22.55% in pre-market trading, marking a significant rise in its stock price.

D. Boral Capital has upgraded Cero Therapeutics (CERO) from Hold to Buy, setting a target price of $30. The firm highlights several potential catalysts on the horizon, including rapid proof of concept, additional capital, and key inflection points that could drive meaningful stock appreciation. The positive outlook is based on the company’s differentiated approach to T cell engineering and the belief that the shares are undervalued relative to the company’s innovation potential.

Cero Therapeutics has shown remarkable momentum, gaining over 55% in the past week. The company recently announced that the first patient in its Phase 1 trial of CER-1236 completed the dose-limiting toxicity observation period with no reported dose-limiting toxicities. This positive development has contributed to the bullish sentiment surrounding the stock.

Analysts have expressed a broadly bullish sentiment across sectors, with the majority of ratings being “Buy” and several upward price target adjustments. The company’s innovative approach to T cell engineering and the positive results from its clinical trials have positioned it well for future growth and stock appreciation.